TuHURA Biosciences (NASDAQ:HURA) Earns Buy Rating from Analysts at Maxim Group

Maxim Group started coverage on shares of TuHURA Biosciences (NASDAQ:HURA) in a report issued on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $15.00 target price on the stock.

TuHURA Biosciences Price Performance

TuHURA Biosciences stock opened at $5.27 on Tuesday. The stock has a market cap of $8.38 million, a P/E ratio of -0.04 and a beta of 0.82. TuHURA Biosciences has a 52 week low of $2.84 and a 52 week high of $23.73.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.